Lupin acquires speciality product portfolio in Germany

Enables Indian company to bring broadened CNS portfolio to German market

Indian generics pharmaceutical firm Lupin has agreed to buy Temmler's speciality product portfolio subject to certain closing conditions.

Temmler, based in Marburg, Germany, is part of the Aenova Group, a German contract manufacturer. The company has a fast-growing speciality portfolio of 13 products including Central Nervous System (CNS) products and drugs that address rare diseases such as Myasthenia Gravis and Huntington disease, as well as fast-growing dermatology products for anti-wart treatment. Since Huntington disease has many symptoms ranging from motoric symptoms to personality changes, both Temmler and Lupin's Hormosan products can be used to treat the disease.

No financial details about the transaction have been revealed.

Vinita Gupta, Chief Executive of Mumbai-based Lupin, said: 'We are very pleased to add to our speciality business with this acquisition. Temmler's business has a strong strategic fit with Lupin's Hormosan business in Germany and enables Lupin to bring an enhanced speciality CNS portfolio to the German market.'

Aenova Group's CFO Frank Elsen added: 'I believe that Lupin is perfectly poised to take Temmler's product portfolio and its growth forward. We are extremely optimistic about this strategic agreement which allows us to concentrate on our core business. As a leading CDMO we are proud to continue to manufacture and supply at highest quality all related products to our partner Lupin.'

Companies